Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Minerva Neurosciences, Inc. (NERV) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
08/15/2023 ARS Form ARS - Annual Report to Security Holders:
08/15/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/15/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/04/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/01/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/03/2023 D Form D - Notice of Exempt Offering of Securities:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia"
04/20/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/08/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Point72 Asset Management, L.P. reports a 0% stake in Minerva Neurosciences, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 3.6% stake in Minerva Neurosciences Inc.
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 22.5% stake in MINERVA NEUROSCIENCES, INC.
12/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. [email protected] Media inquiries:"
12/16/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. [email protected] Media inquiries:"
09/26/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/14/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
09/09/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market BURLINGTON, Mass. - September 9, 2022 - Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported a listing transfer from The Nasdaq Global Market to The Nasdaq Capital Market. The Company announced today that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market that the Company's application to transfer its common stock from The Nasdaq Global Market to The Nasdaq Capital Market, as allowed under Listing Rule 5810, had been approved. The Company's common stock will begin trading on The Nasdaq Capital Market effective at the start of trading on September 12, 2022. T..."
08/23/2022 SC 13G Point72 Asset Management, L.P. reports a 8.8% stake in Minerva Neurosciences, Inc.
08/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. [email protected] Media inquiries:"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/17/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy